Chile remains on USTR Priority Watch list

6 May 2011

The Office of the United States Trade Representative (USTR) released its annual Special 301 Report on the adequacy and effectiveness of US trading partners’ protection of intellectual property rights (IPR). Despite its efforts Chile remains on the Priority Watch List for fifth year. Argentina and Venezuela are included too.

The report says: “The United States welcomes the Pinera Administration's significant commitment to address outstanding IPR issues under the United States-Chile Free Trade Agreement (FTA) in 2011. Positive steps taken in 2010 include the launch of a Ministerial-level interagency committee on IPR with a mandate to examine these issues, and the implementation of the new copyright legislation. In addition, Chile ratified the Convention Relating to the Distribution of Program-Carrying Signals Transmitted by Satellites (Brussels Convention) and the Trademark Law Treaty. The United States encourages Chile to take further action by acceding to, and ratifying, the International Convention for the Protection of New Varieties of Plants.”

The USA also encourages Chile to implement its commitment to provide an effective system to address patent issues expeditiously in connection with applications to market pharmaceutical products, to implement protections against the circumvention of technological protection measures, to implement protection for encrypted program-carrying satellite signals, and to ensure that administrative and judicial procedures and deterrent remedies are made available to rights holders.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Generics